Sugi Predict

Sugi Predict / Compounds / SCHEMBL11023739

SCHEMBL11023739

SCHEMBL11023739

COC(=O)c1nc(Cl)cc(Cl)c1N

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 6/20 0.48
▸ KDM4E B2RXH2 7/20 0.46
▸ PKM P14618 2/20 0.46
▸ RCE1 Q9Y256 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ALDH1A1 P00352 6/20 0.42
▸ SMN1; SMN2 Q16637 5/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GAA P10253 1/20 0.41
▸ ABL1 P00519 1/20 0.40
▸ S1PR4 O95977 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ ADCY10 Q96PN6 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30544220 1.00 NQO2 (0.48) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL30668009 0.85 NPSR1 (0.44) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL18124756 0.85 NPSR1 (0.44) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL27509793 0.83 GAA (0.46) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL31330704 0.83 NPSR1 (0.42) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL535659 0.83 NPSR1 (0.42) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL2133062 0.82 NPSR1 (0.48) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL16147177 0.82 CNR1 (0.41) NQO2NPSR1ALDH1A1KMT2A
SCHEMBL26289357 0.81 NPSR1 (0.47) NQO2KDM4EPKMRCE1NPSR1
SCHEMBL25201752 0.79 SCN10A (0.40) NQO2ALDH1A1L3MBTL1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-07 — — US disclosed
US-20250304580-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-10-02 — — US disclosed
US-20250042897-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-02-06 — — US disclosed
EP-4479388-A1 ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS Gilead Sciences, Inc. (US) 2024-12-25 — — EP disclosed
EP-4430029-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE Vigil Neuroscience, Inc. (US) 2024-09-18 — — EP disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 — — US disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 — — US disclosed
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-09-21 — — US disclosed
WO-2023154905-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-08-17 — — WO disclosed
WO-2023154905-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS GILEAD SCIENCES, INC. (US) 2023-08-17 — — WO disclosed
EP-4192836-A1 ATR INHIBITORS AND USES THEREOF ANTENGENE DISCOVERY LIMITED (CN) 2023-06-14 — — EP disclosed
WO-2023086800-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 — — WO disclosed
WO-2023086800-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2023-05-19 — — WO disclosed
WO-2022028598-A1 ATR INHIBITORS AND USES THEREOF SHANGHAI ANTENGENE CORPORATION LIMITED (CN) 2022-02-10 — — WO disclosed
US-8835409-B2 3-alkenyl-6-halo-4-aminopicolinates and their use as herbicides DOW AGROSCIENCES, LLC. (US) 2014-09-16 — — US disclosed
US-8835409-B2 3-alkenyl-6-halo-4-aminopicolinates and their use as herbicides DOW AGROSCIENCES, LLC. (US) 2014-09-16 — — US disclosed
US-8835409-B2 3-alkenyl-6-halo-4-aminopicolinates and their use as herbicides DOW AGROSCIENCES, LLC. (US) 2014-09-16 — — US disclosed
US-20120190548-A1 3-ALKENYL-6-HALO-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2012-07-26 — — US disclosed
US-20120190548-A1 3-ALKENYL-6-HALO-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2012-07-26 — — US disclosed
US-20120190548-A1 3-ALKENYL-6-HALO-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124198-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, CCR1, CCR6 NQO2 4257/4885KDM4E 427/4885PKM 2277/4885
US-20250304580-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 NQO2 2711/4885KDM4E 3817/4885PKM 3090/4885
US-20230295166-A1 ATR INHIBITORS AND USES THEREOF ATR, CHEK1, CHEK2 NQO2 2421/4885KDM4E 2648/4885PKM 1602/4885
US-20250042897-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 NQO2 3022/4885KDM4E 3909/4885PKM 3128/4885
US-20120190548-A1 3-ALKENYL-6-HALO-4-AMINOPICOLINATES AND THEIR USE AS HERBICIDES ATL3, AAAS, HDHD5 NQO2 2006/4885KDM4E 1379/4885PKM 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.